Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for DNA Damage Response (DDR) and Oncology Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BRIP1/FANCJ drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BRIP1 Recombinant Protein (WT / Mutant) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for ATPase and helicase assays. |
View BRIP1 Products |
| Gene Delivery | BRIP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and G-quadruplex rescue assays. |
View BRIP1 Products |
| Benchmark Ab | Anti-BRIP1 Recombinant Antibody Recombinant positive control for Western Blot, IP, and IHC validation. |
View BRIP1 Products |
| Validator | BRIP1 siRNA Set For target knockdown verification and synthetic lethality screening. |
View BRIP1 Products |
| Related Target A | BRCA1 Direct interaction partner. Critical for HR repair pathway and synthetic lethality profiling. |
View BRCA1 Products |
| Related Target B | PARP1 Synergistic target; BRIP1 deficiency sensitizes cells to PARP inhibitors. |
View PARP1 Products |
| Related Target C | WRN RecQ helicase family member. Critical counter-screening target for selectivity. |
View WRN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Helicase/ATPase activity evaluation | High-purity (>95%) active recombinant proteins with verified sequences and theoretical MW. |
| Selectivity screening (RecQ/Fe-S family) | Comprehensive homolog panel including WRN, BLM, and FANC family proteins. |
| Lack of Controls | Sequence-verified clinical-grade benchmark recombinant antibodies included |
| False Positives in Small Molecule Screens | Validated siRNA pools included for target-specific knockdown rescue validation |
Live BRIP1/FANCJ R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BRIP1/FANCJ therapeutics is intensifying, with major players shifting focus from traditional DNA damage response (DDR) targets to novel synthetic lethality nodes. As first-generation PARP inhibitors face resistance challenges, the next wave of R&D is targeting BRIP1/FANCJ helicase activity to exploit homologous recombination deficiencies in BRCA-mutant and HR-proficient ovarian and breast cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Artios Pharma, Repare Therapeutics | Ovarian Cancer, Breast Cancer, Solid Tumors | Enzymatic Assay (Need high-purity active recombinant BRIP1 helicase) |
| Synthetic Lethality Combination | AstraZeneca, Ideaya Biosciences | PARPi-resistant Tumors | Cell-based Knockdown Validation (Need validated BRIP1 siRNA) |
| Gene Therapy / Rescue | Academic Institutes | Fanconi Anemia, Genetic Disorders | Stable Overexpression (Need Lentivirus Premade Particles) |